Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20209084 | 0.95 | DUSP3 (0.32) | DUSP3AHRSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL26490571 | 0.93 | SIGMAR1 (0.36) | DUSP3AHRSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL26490669 | 0.93 | MCL1 (0.34) | KDM4EALDH1A1CYP1A2 | |
| SCHEMBL14295286 | 0.92 | AHR (0.41) | DUSP3AHRSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL6373470 | 0.92 | AHR (0.41) | DUSP3AHRSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL18802547 | 0.90 | MAPT (0.37) | DUSP3AHRKDM4EALDH1A1MAPT | |
| SCHEMBL26490594 | 0.90 | KDM4E (0.35) | AHRSIGMAR1KDM4EALDH1A1MAPT | |
| SCHEMBL15138510 | 0.90 | AHR (0.39) | DUSP3AHRSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL19103111 | 0.90 | MMP12 (0.36) | DUSP3AHRSIGMAR1KDM4EALDH1A1 | |
| SCHEMBL17740635 | 0.90 | MMP12 (0.36) | DUSP3AHRSIGMAR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120319091-A1 | AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-12-20 | — | — | US | disclosed |
| US-20120319091-A1 | AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120319091-A1 | AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | INMT, TYR, ALKBH2 | DUSP3 3590/4885AHR 147/4885SIGMAR1 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.